A patient with gastric cancer and liver metastases successfully treated with combination chemotherapy including S-1.
We report the case of a 62-year-old man with advanced gastric cancer and multiple liver metastases who was successfully treated with combined chemotherapy including S-1. The patient was clinically diagnosed with stage IV (T3 N2 H1 P0) disease and was initially treated with 100 mg/body per day S-1 administered orally for 21 days and 10 mg/body per day cisplatin (CDDP) infused on days 1-5, 8-12, and 15-19. This chemotherapy resulted in significant reduction of the liver and gastric tumors. After receiving additional CDDP/S-1 administration as an outpatient, the patient's liver masses disappeared as shown on abdominal computed tomography (CT). With the patient's desire and informed consent, he underwent curative surgery with total gastrectomy, D1+alpha lymph node dissection, and partial resection of liver S4. After discharge without any surgical complication, CT revealed regrowth of the S4 liver mass, and combined docetaxel and CDDP was selected as second-line chemotherapy with local radiation therapy against the hepatic metastasis. Additionally, a third regimen with irinotecan and S-1 was given. At 2 years 7 months after the initial treatment, no sign of cancer (including liver metastasis and peritoneal dissemination) has been identified by radiological follow-up examinations.
Nakamura
Rieko
R
Department of Surgery, School of Medicine, Keio University, Shinanomachi 35, Shinjuku-ku, Tokyo, 160-8582, Japan.
Saikawa
Yoshiro
Y
Kumagai
Koushi
K
Kiyota
Tsuyoshi
T
Ohashi
Masaki
M
Yoshida
Masashi
M
Kubota
Tetsuro
T
Kumai
Koichiro
K
Kitajima
Masaki
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D000077143:Docetaxel; D004338:Drug Combinations; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D043823:Taxoids / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use*
D004338:Drug Combinations; D043823:Taxoids; C079198:S 1 (combination); D005641:Tegafur; D000077143:Docetaxel; D010094:Oxonic Acid; D002945:Cisplatin
Am J Surg. 2001 Mar;181(3):279-83
11376587
Ann Oncol. 2003;14 Suppl 2:ii41-4
12810457
Cancer Chemother Pharmacol. 1998;42(5):391-9
9771954
Oncol Rep. 2002 Jan-Feb;9(1):89-92
11748462
Gastric Cancer. 2003;6 Suppl 1:50-7
12775021
J Clin Oncol. 2003 Jan 1;21(1):54-9
12506170
Oncology. 2001;61(1):16-22
11474243
Cancer Sci. 2004 Aug;95(8):679-84
15298732
J Clin Oncol. 2000 Jul;18(14):2648-57
10894863
Oncol Rep. 2003 Mar-Apr;10(2):381-6
12579276
Surgery. 1993 Oct;114(4):799-805; discussion 804-5
8211697
Oncol Rep. 2005 May;13(5):865-70
15809751
Ann Surg Oncol. 1997 Apr-May;4(3):203-8
9142380
Oncology. 1999 Oct;57(3):202-10
10545788
Ann Surg. 2002 Jan;235(1):86-91
11753046
Int J Clin Oncol. 2002 Oct;7(5):326-9
12402069
Oncology. 2000 Apr;58(3):191-7
10765119
Eur J Cancer. 2003 Nov;39(16):2328-33
14556924
J Gastroenterol. 2000 Dec;35(12):907-11
11573726
Oncology (Williston Park). 2002 May;16(5 Suppl 5):16-8
12109800
Eur J Cancer. 1998 Oct;34(11):1715-20
9893658
Br J Cancer. 2003 Dec 15;89(12):2207-12
14676796
N Engl J Med. 2001 Sep 6;345(10):725-30
11547741
J Clin Oncol. 1999 Jan;17 (1):319-23
10458249
Oncology. 2000 Jun;59(1):14-7
10895060
Oncol Rep. 2003 May-Jun;10 (3):687-91
12684644